Trident Lifeline Limited, originally established as Trident Lifeline Private Limited in 2014, transitioned to a public entity in 2022. The company specializes in the marketing and distribution of ethical pharmaceutical products both domestically and internationally. Utilizing a third-party distribution network, Trident offers a diverse portfolio of pharmaceutical formulations manufactured under contract agreements. The company maintains a global presence with registered or in-process product registrations in regions including Africa, Latin America, and East India, covering countries like Bolivia, Kenya, and Venezuela.
Trident Lifeline's product range encompasses various forms such as capsules, tablets, and gels, addressing medical needs across multiple therapeutic areas including antibacterial, anti-diabetic, and anti-inflammatory drugs. The company's operations are supported by FDA and WHO-approved contract manufacturing facilities, ensuring compliance and quality. As of May 2022, Trident Lifeline manages 832 products under different brand names, with a significant number of products registered or in the process of registration internationally. The company is ISO 9001:2015 certified, underscoring its commitment to quality management.
